Symbol="IMPL"
AssetType="Common Stock"
Name="Impel Neuropharma Inc"
Description="Impel NeuroPharma, Inc., an advanced-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from diseases of the central nervous system in the United States. The company is headquartered in Seattle, Washington."
CIK="1445499"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="201 ELLIOTT AVE. W, SUITE 260, SEATTLE, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="25648900"
EBITDA="-82251000"
PERatio="None"
PEGRatio="None"
BookValue="-3.07"
DividendPerShare="0"
DividendYield="0"
EPS="-4.27"
RevenuePerShareTTM="0.647"
ProfitMargin="0"
OperatingMarginTTM="-5.46"
ReturnOnAssetsTTM="-0.491"
ReturnOnEquityTTM="-25.46"
RevenueTTM="15265000"
GrossProfitTTM="6157000"
DilutedEPSTTM="-4.27"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.486"
AnalystTargetPrice="18"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="10.37"
PriceToBookRatio="18.46"
EVToRevenue="6.84"
EVToEBITDA="-0.639"
Beta="-0.112"
num_52WeekHigh="8.05"
num_52WeekLow="0.55"
num_50DayMovingAverage="1.363"
num_200DayMovingAverage="2.175"
SharesOutstanding="23749000"
DividendDate="None"
ExDividendDate="None"
symbol="IMPL"
open="0.57"
high="0.65"
low="0.54"
price="0.62"
volume="818217.00"
latest_trading_day="2023-08-16"
previous_close="1.08"
change="-0.46"
change_percent="-42.5000%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="71"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="TRUE"
Aroon_momentum="29"
Volume_recent_avg="461428"
Change_recent_avg="-0.01"
Delta_recent_avg="0.17"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="-0.81"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="TRUE"
Aroon_momentum_positive="29"
Aroon_momentum_negative="71"
image_negative_thumbnail_id_1="141"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0035.jpeg"
image_negative_thumbnail_id_2="121"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0055.jpeg"
image_neutral_thumbnail_id_1="525"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0074.jpeg"
image_neutral_thumbnail_id_2="568"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_positive_thumbnail_id_1="984"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0146.jpeg"
image_positive_thumbnail_id_2="653"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0055.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1184"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
